Clinical trials: Fulvestrant
Systemic Lupus Erythematosus
Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies
SLE(Systemic Lupus Erythematosus) is an autoimmune disese that primarily occurs in women(9:1 compared to men). The disease is activated by genetic and environmental factors, yet the female gender is the strongest risk factor.
- Trial name
- NCT00417430
- Testing
- ICI 182,780 (Faslodex)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- The Center for Rheumatic Disease, Allergy, & Immunology
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Breast Neoplasm
A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer
This pilot trial evaluates in vivo megestrol acetate (MA) modulation of steroidal receptors in advanced breast cancer.
- Trial name
- MEGA (NCT03024580)
- Testing
- Megestrol Acetate 160Mg Tablet, Anastrozole 1Mg Tablet, Letrozole 2.5Mg Tablet
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Instituto Nacional de Cancer, Brazil
Breast Cancer
Maintenance Hormone Therapy for Postmenopausal HR Positive Advanced Breast Cancer
This is a prospective, single arm phase II study to evaluate the efficacy and safety of fulvestrant as a maintenance hormone therapy after first-line chemotherapy for postmenopausal HR positive advanced breast cancer.
- Trial name
- FANCY (NCT02000193)
- Testing
- fulvestrant
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Puberty, Precocious, McCune-Albright Syndrome
Faslodex in McCune-Albright Syndrome
The purpose of this study is to evaluate the safety, effectiveness and pharmacokinetics of a study drug called Faslodex (fulvestrant) in the treatment of progressive precocious puberty (PPP) (early puberty) in girls with…
- Trial name
- FMAS (NCT00278915)
- Testing
- Fulvestrant
- Where
- 16 sites in United States, France and 4 more
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Breast Cancer
Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
the purpose of this study is to describe the way Faslodex is used in France, in patients suffering from initial breast cancer, that is to evaluate Faslodex treatment duration and to determine patients profile
- Trial name
- NCT00681369
- Volunteers
- 217 people
- Sponsor
- AstraZeneca
Metastatic Breast Cancer
Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed
- Trial name
- NCT07008963
- Testing
- non-interventional
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- AstraZeneca
Breast Cancer
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
This study is a post-authorisation study, committed to Center for Drug Evaluation (CDE) and China Food and Drug Administration (CFDA), in order to provide more effectiveness and safety data about Faslodex in real world clinical…
- Trial name
- NCT01425294
- Where
- 23 sites in China
- Volunteers
- 231 people
- Sponsor
- AstraZeneca
Breast Cancer
Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients
What Comes After Fulvestrant? A Real World Multicenter Retrospective Study-Treatment After Progression of Fulvestrant Among Metastatic Breast Cancer Patients in China.
- Trial name
- NCT03541863
- Where
- China
- Volunteers
- 131 people
- Sponsor
- Fudan University
Breast Cancer
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
The purpose of this study is to determine the efficacy of anastrozole monotherapy versus maximal oestrogen blockade with combinated therapy of fulvestrant and anastrozole compared with in treatment of hormone receptor positive…
- Trial name
- FACT (NCT00256698)
- Testing
- Fulvestrant, Anastrozole
- Where
- 85 sites in Canada, Costa Rica and 10 more
- Volunteers
- 514 people
- Sponsor
- AstraZeneca
Breast Cancer
Efficacy of Anastrozole and Fulvestrant in Patients With ER Positive, HER2 Negative, Operable Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using anastrozole or fulvestrant may fight breast cancer by lowering the amount of estrogen the body makes or by blocking the use of estrogen by the…
- Trial name
- NIMFEA (NCT00629616)
- Testing
- anastrozole, fulvestrant
- Where
- 6 sites in France
- Volunteers
- 116 people
- Sponsor
- UNICANCER
Breast Cancer
Fulvestrant or Tamoxifen in Treating Postmenopausal Women Who Are Undergoing Surgery for Ductal Carcinoma in Situ of the Breast
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant or tamoxifen may fight breast cancer by blocking the use of estrogen by the tumor cells.
- Trial name
- NCT00126464
- Testing
- fulvestrant, tamoxifen citrate, conventional surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cedars-Sinai Medical Center
Breast Neoplasms
A Study to Understand About the Study Medicine Palbociclib in Breast Cancer Patients After it is Out in the Japanese Market
The purpose of the study is to: compare the chances of getting interstitial lung disease (ILD) in new users of palbociclib plus fulvestrant to new users of fulvestrant alone (using data from before palbociclib was out in the…
- Trial name
- NCT07096024
- Testing
- palbociclib plus fulvestrant, fulvestrant
- Where
- United States
- Volunteers
- 95,637 people
- Sponsor
- Pfizer
Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing.
- Conditions
- Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm
- Trial name
- NCT05564377
- Testing
- Alpelisib, Binimetinib, Biopsy Procedure
- Where
- 484 sites in United States, Puerto Rico
- Volunteers
- 2,900 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases.
- Trial name
- NCT00010153
- Testing
- fulvestrant, conventional surgery
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Metastatic Breast Cancer
Faslodex Registry: Fulvestrant in Current Clinical Practice
The sequential administration of endocrine therapies to patients with advanced breast cancer requires the availability of therapies with different modes of actions, so that tumours developing resistance to one agent are not cross…
- Trial name
- NCT00735215
- Where
- 12 sites in Belgium
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Breast Cancer
Faslodex Post Marketing Surveillance
This PMS aims to assess the efficacy, the safety and tolerability profile of Faslodex in everyday practice. Secondary objective of this PMS is to identify the frequency of serious adverse events or any unknown adverse events of…
- Trial name
- NCT00860561
- Where
- 7 sites in South Korea
- Volunteers
- 42 people
- Sponsor
- AstraZeneca
Breast Cancer
Pre-operative Hormonal Treatment for Hormone Receptor Positive Breast Cancer
To investigate prospectively whether short term endocrine treatment can induce molecular changes, predictive for therapy response.
- Trial name
- NCT00738777
- Testing
- Anastrozole, Anastrozole+Fulvestrant, Tamoxifen
- Where
- 4 sites in Netherlands
- Volunteers
- 250 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Fulvestrant 500mg With Exemestane Endocrine Therapy for Postmenopausal Advanced Breast Cancer Patients
A Randomized, Open label, Parallel-group, Multi-center study. Eligible patients will be randomized in a 1:1 ratio to receive fulvestrant 500 mg or Exemestane 25mg.
- Trial name
- FRIEND (NCT02646735)
- Testing
- Fulvestrant 500 mg, Exemestane 25 mg
- Where
- China
- Volunteers
- 148 people
- Sponsor
- Chinese Academy of Medical Sciences
PIK3CA-Related Overgrowth Spectrum (PROS), Breast Neoplasms (Including Advanced or Metastatic Breast Cancer With PIK3CA Mutation)
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
The purpose of this study is to provide post-trial access to alpelisib and to assess its long-term safety when administered as a single agent or in combination with other drugs.
- Trial name
- EPIK-RO (NCT07679269)
- Testing
- Alpelisib, Fulvestrant, Trastuzumab
- Volunteers
- 51 people
- Sponsor
- Novartis Pharmaceuticals